Pharmaceuticals US

US Treatment-Resistant Depression Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

US Treatment-Resistant Depression Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $878.3 Mn Placeholder estimate
Estimate 2025 $931.9 Mn 39.9% of the global market
Projected 2034 $1.59 Bn 70.4% Adds $655.9 Mn over 9 forecast years
CAGR 2025–2034 6.1% Faster than 51% of 180 Pharmaceuticals markets here
Key players 5
  • US is 39.95% of the global market.
  • In North America, the largest is US (this report) at $931.9 Mn.
  • Fastest growing: Canada at 8% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$655.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Treatment-Resistant Depression Drugs Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $878.3 Mn — —
2025 (base) $931.9 Mn +$53.6 Mn —
2026 (forecast) $988.7 Mn +$56.8 Mn +6.1%
2027 (forecast) $1.05 Bn +$60.3 Mn +12.6%
2028 (forecast) $1.11 Bn +$64.0 Mn +19.4%
2029 (forecast) $1.18 Bn +$67.9 Mn +26.7%
2030 (forecast) $1.25 Bn +$72.0 Mn +34.5%
2031 (forecast) $1.33 Bn +$76.4 Mn +42.7%
2032 (forecast) $1.41 Bn +$81.1 Mn +51.4%
2033 (forecast) $1.50 Bn +$86.0 Mn +60.6%
2034 (forecast) $1.59 Bn +$91.3 Mn +70.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Treatment-Resistant Depression Drugs Market Analysis at a glance
Market size, 2025$931.9 Mn placeholder estimate
Forecast, 2034$1.59 Bn placeholder estimate
Growth (CAGR), 2025–20346.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersJohnson & Johnson, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Axsome Therapeutics, Compass Pathways (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials77 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Treatment-Resistant Depression Drugs Market Analysis Executive Summary

Treatment-resistant depression drugs help people whose depression has not improved with at least two standard antidepressants.

Key segments of the treatment-Resistant Depression Drugs market include drug class (NMDA Antagonists, Atypical Antipsychotic Add-Ons and Psychedelics) and route (Oral, Intranasal and Intravenous).

Bar chart: US Treatment-Resistant Depression Drugs market size, 2024–2034, placeholder estimates. $878.3 Mn in 2024, $931.9 Mn in 2025 and $1.59 Bn in 2034, 6.1% CAGR.
US Treatment-Resistant Depression Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Treatment-Resistant Depression Drugs Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the treatment-Resistant Depression Drugs market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the treatment-Resistant Depression Drugs market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the treatment-Resistant Depression Drugs market.

Competitive Landscape for Treatment-Resistant Depression Drugs Market in US

The treatment-Resistant Depression Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Treatment-Resistant Depression Drugs Market in US

Treatment-Resistant Depression Drugs in the US: rules, payment and research

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 77 studies on Treatment-Resistant Depression Drugs that are recruiting, active or about to start in the US.⁠[3] Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure for the US.⁠[4]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for treatment-Resistant Depression Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Treatment-Resistant Depression Drugs right now, from free public sources.

Clinical trials

77 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Motif Neurotech, Inc. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. LivaNova PLC 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 3,145 papers since 2021 (worldwide)

  1. Nogo-related frontal theta-band activity after magnetic seizure therapy in treatment-resistant depression: an exploratory task-based EEG study. Frontiers in psychiatry, 2026
  2. Ketamine for Treatment-Resistant Depression. Journal of the American Psychiatric Nurses Association, 2026
  3. From Rapid Synaptic Events to Lasting Antidepressant States: Convergent and Divergent Mechanisms of Ketamine and Psychedelics. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2026
  4. Treatment-Resistant Depression Is Not a Single Disorder. Journal of psychiatric practice, 2026
  5. Treatment-Resistant Depression. Journal of psychiatric practice, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Treatment-Resistant Depression Drugs in context

The US compared

  • Suicide rate: 14.0 per 100,000 people (2023). World: 9.2 per 100,000 people (2023).[1]
  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[2]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Treatment-Resistant Depression Drugs market in the US?
Placeholder estimate: about $931.9 Mn in 2025, rising to about $1.59 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Treatment-Resistant Depression Drugs market in the US growing?
Placeholder estimate: about 6.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Treatment-Resistant Depression Drugs market report cover?
The report splits the market by drug class (NMDA Antagonists, Atypical Antipsychotic Add-Ons, Psychedelics, Others), route (Oral, Intranasal, Intravenous) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Treatment-Resistant Depression Drugs market?
Key players include Johnson & Johnson, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Axsome Therapeutics and Compass Pathways.
What is driving the Treatment-Resistant Depression Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the treatment-Resistant Depression Drugs market. Governments and employers are investing more in mental health care.
Who regulates Treatment-Resistant Depression Drugs in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Treatment-Resistant Depression Drugs are running in the US?
77 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on mental health

See the topic